Compare Smith & Nephew plc with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
GBP 9,577 Million (Large Cap)
25.00
NA
768.48%
0.50
9.71%
2.44
Revenue and Profits:
Net Sales:
789 Million
(Quarterly Results - Dec 2014)
Net Profit:
101 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-6.68%
0%
-6.68%
6 Months
-8.8%
0%
-8.8%
1 Year
4.75%
0%
4.75%
2 Years
13.54%
0%
13.54%
3 Years
-9.49%
0%
-9.49%
4 Years
-1.53%
0%
-1.53%
5 Years
-26.4%
0%
-26.4%
Smith & Nephew plc for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
3.07%
EBIT Growth (5y)
3.16%
EBIT to Interest (avg)
67.31
Debt to EBITDA (avg)
0.43
Net Debt to Equity (avg)
0.49
Sales to Capital Employed (avg)
0.43
Tax Ratio
29.67%
Dividend Payout Ratio
52.94%
Pledged Shares
0
Institutional Holding
0.02%
ROCE (avg)
22.98%
ROE (avg)
18.53%
Valuation key factors
Factor
Value
P/E Ratio
25
Industry P/E
Price to Book Value
2.44
EV to EBIT
19.88
EV to EBITDA
13.73
EV to Capital Employed
1.96
EV to Sales
4.11
PEG Ratio
NA
Dividend Yield
768.48%
ROCE (Latest)
9.86%
ROE (Latest)
9.71%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Bullish
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 2 Foreign Institutions (0.01%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'14 - YoY
Dec'14
Dec'13
Change(%)
Net Sales
789.00
725.90
8.69%
Operating Profit (PBDIT) excl Other Income
273.50
219.30
24.72%
Interest
13.30
1.90
600.00%
Exceptional Items
-36.60
-21.00
-74.29%
Consolidate Net Profit
101.10
100.10
1.00%
Operating Profit Margin (Excl OI)
251.40%
228.90%
2.25%
USD in Million.
Net Sales
YoY Growth in quarter ended Dec 2014 is 8.69% vs 8.23% in Dec 2013
Consolidated Net Profit
YoY Growth in quarter ended Dec 2014 is 1.00% vs 13.24% in Dec 2013
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
4,677.20
4,546.80
2.87%
Operating Profit (PBDIT) excl Other Income
1,238.30
1,196.60
3.48%
Interest
107.00
117.40
-8.86%
Exceptional Items
-175.30
-230.90
24.08%
Consolidate Net Profit
474.20
322.40
47.08%
Operating Profit Margin (Excl OI)
171.60%
167.60%
0.40%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 2.87% vs 1.85% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 47.08% vs 52.36% in Dec 2024
About Smith & Nephew plc 
Smith & Nephew plc
Pharmaceuticals & Biotechnology
Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices. The Sports Medicine Joint Repair franchise offers surgeons a range of instruments, technologies and implants necessary to perform minimally invasive surgery of the joints, including the repair of soft tissue injuries and degenerative conditions of the knee, hip and shoulder. The AET franchise offers an array of minimally invasive surgery-enabling systems and devices. The Trauma & Extremities franchise supports healthcare professionals with solutions used by surgeons to stabilize severe fractures, correct bone deformities, treat arthritis and heal soft tissue complications.
Company Coordinates 
Company Details
Building 5, Croxley Park, Hatters Lane , WATFORD None : WD18 8YE
Registrar Details






